Home/Pipeline/Cannabics® RCC-33

Cannabics® RCC-33

Colorectal Cancer

PreclinicalActive

Key Facts

Indication

Colorectal Cancer

Phase

Preclinical

Status

Active

Company

CNBX Pharmaceuticals

About CNBX Pharmaceuticals

CNBX Pharmaceuticals is a clinical-stage biotech company developing a pipeline of cannabinoid-based drug candidates for cancer and neuropsychiatric disorders. Its core asset, RCC-33, is positioned as a first-in-class candidate for colorectal cancer, currently in late preclinical stages preparing for an IND. The company utilizes an in-house drug discovery platform centered on high-throughput screening of cannabinoid formulations against various cancer types. Leadership combines business acumen with scientific and clinical expertise, supported by a notable advisory board in oncology.

View full company profile

Therapeutic Areas

Oncology Neuropsychiatry Gastroenterology

Other Colorectal Cancer Drugs

Drug	Company	Phase	Status
CY-101 + Pembrolizumab	Cytovation	Phase 1/2	Initiate 1H-26
Leronlimab	CytoDyn	Phase 2	Phase in progress
EGFR inhibitor	Acellera	Pre-clinical	Hit Identification
VCR-036	Vicero Bio	Preclinical	Active
CBI-1214	Cartography Biosciences	Phase 1	Active
QL335	QLSF Biotherapeutics	Phase 1	Active
Colorectal Cancer Detection Partnership	Daisy Genomics	Research/Assay Development	Active
High Internalization ADC	Lytica Therapeutics	Preclinical	Active
Undisclosed Colorectal Program(s)	Tavanta Therapeutics	Phase 2	Active
KRAS AK™PCR Mutation Screen Kit	Akcell Biotech	Commercial	Active
Program not named	Reponex	Pre-clinical	Active
Colorectal Cancer Screening Test	Metabiomics	Approved	Active